Abstract: The invention provides methods and compositions for treating urothelial carcinoma in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient as a neoadjuvant or an adjuvant therapy based on the presence or level of ctDNA in a biological sample obtained from the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating urothelial carcinoma in a patient.

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer (e.g., bladder cancer (e.g., UC) or kidney cancer (e.g., RCC)). The invention provides methods of identifying an individual having a cancer who is likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, methods for selecting a therapy for an individual having a cancer, methods of identifying an individual having a cancer who is less likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist monotherapy, methods of monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, and methods of treating an individual having cancer, based on expression levels of a biomarker of the invention (e.g., one or more genes set forth in any one of Tables 1-7, e.g., IL8).

Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.